A screening program only works if people actually show up.
FIT is a simple, non-invasive fecal test detecting 92% of colorectal cancers, requiring no dietary restrictions and delivering rapid results at lower cost than traditional methods. Colorectal cancer is Brazil's second most common cancer type, with 53.8k new diagnoses annually and nearly 24k deaths in 2023, disproportionately affecting those over 50.
- FIT test detects 92% of colorectal cancers with no dietary restrictions required
- Colorectal cancer caused nearly 24,000 deaths in Brazil in 2023
- Estimated 53,800 new diagnoses annually in Brazil during 2026-2028
- Program targets 40 million asymptomatic adults aged 50-75
- Chemotherapy procedures increased 20% from 2022 to 2025 in Brazil's public system
Brazil's health ministry launches FIT immunochemical testing as the standard screening tool for asymptomatic adults aged 50-75, potentially reaching 40 million Brazilians and reducing colorectal cancer mortality.
Brazil's health ministry has adopted a new screening protocol for colorectal cancer that will make a simple fecal test available to more than 40 million citizens starting in the second half of 2026. Health Minister Alexandre Padilha announced the initiative on May 21 in Lyon, France, positioning it as the country's first systematic approach to early detection of a disease that kills nearly 24,000 Brazilians annually and ranks as the second most common cancer in the nation.
The test in question is called the Immunochemical Fecal Test, or FIT. It works much like a home pregnancy test—a quick strip that detects microscopic traces of blood in stool samples. Those traces can signal the presence of polyps, precancerous lesions, or cancer itself in the colon and rectum. The elegance of FIT lies in its simplicity: no special diet required beforehand, no complex machinery needed to administer it, results arrive quickly, and it catches roughly 92 percent of colorectal cancers. The cost is substantially lower than traditional screening methods, and the test can be performed in primary care clinics rather than specialized facilities. When FIT results suggest concern, patients move to colonoscopy—the definitive diagnostic tool—rather than subjecting everyone to that more invasive procedure.
The announcement arrived during Maio Roxo, a campaign focused on inflammatory bowel diseases like Crohn's disease and ulcerative colitis, both of which increase colorectal cancer risk. The screening initiative fits within a broader federal effort called Agora Tem Especialistas, which aims to build the country's largest public network for cancer prevention, diagnosis, and treatment. According to the health ministry, the strategy will anchor itself in primary care, with FIT as the initial screening tool and specialized imaging and colonoscopy centers standing ready to confirm diagnoses when needed.
Colorectal cancer in Brazil presents a significant public health burden. The National Cancer Institute estimates 53,800 new diagnoses annually during 2026 through 2028. In 2023 alone, the disease caused nearly 24,000 deaths—a mortality rate of 11.3 per 100,000 people. Early-stage tumors often grow silently or produce vague symptoms: irregular bowel habits, abdominal discomfort, a sense of incomplete evacuation, fatigue. By the time symptoms become obvious—blood in stool, unexplained weight loss, anemia, severe abdominal pain—the cancer has often progressed. Risk rises sharply after age 50, and certain factors amplify danger: excess weight, sedentary living, diets heavy in processed meat and light on fiber, family history of the disease, smoking, heavy alcohol use, and inflammatory bowel conditions.
The FIT rollout is one piece of a larger expansion of cancer care. The federal government simultaneously announced funding for 23 high-cost cancer medications previously unavailable through the public system, and for the first time, robotic surgery for oncology will be offered in public hospitals. Breast reconstruction surgery for women who have undergone mastectomy will also become more accessible. These moves respond to surging demand: in 2025, the public health system performed 189,900 radiation therapy procedures, a 22 percent jump from 155,300 in 2022. Chemotherapy sessions climbed 20 percent over the same span, from 3.9 million to 4.7 million treatments annually.
The shift toward systematic screening represents a departure from Brazil's previous approach to colorectal cancer detection. By establishing FIT as the standard entry point for asymptomatic adults between 50 and 75, the health ministry is betting that early identification will drive down mortality and catch more cancers when they remain treatable. Whether the system can absorb the volume of newly identified cases, and whether follow-up colonoscopy capacity will keep pace with screening demand, will determine whether this policy translates into the mortality reduction it promises.
Citações Notáveis
We are announcing the first colorectal cancer screening policy in our system. Based on research and evidence, we will begin a detection strategy anchored in primary care, with fecal testing and support from specialized imaging and colonoscopy centers when necessary.— Health Minister Alexandre Padilha
A Conversa do Hearth Outra perspectiva sobre a história
Why does a country choose to screen for one cancer and not another? What makes colorectal cancer worth this investment right now?
It's the second most common cancer in Brazil, and it kills almost 24,000 people a year. But here's the thing—it's also one of the most preventable. If you catch it early, before symptoms show up, survival rates are dramatically better. The disease often grows quietly for years. By the time someone feels something wrong, it's frequently advanced. A screening program catches it when it's still curable.
The FIT test sounds almost too simple. A strip that detects blood in stool. Why wasn't this the standard years ago?
Cost, partly. Colonoscopy is the gold standard—it's definitive, it can remove polyps during the procedure. But it requires trained specialists, expensive equipment, sedation. You can't scale that to 40 million people overnight. FIT is cheap, fast, doesn't require special preparation. It catches 92 percent of cancers. The strategy here is smart: use FIT to filter out the people who need colonoscopy, rather than sending everyone through the expensive procedure.
Who actually benefits most from this? Is it reaching the people who need it most?
That's the real question. The policy targets people 50 to 75, which is where risk peaks. But colorectal cancer doesn't care about insurance status. The people most likely to die from it—those without regular healthcare access, those with poor diets, those living sedentary lives—are often the hardest to reach. A screening program only works if people actually show up and follow through. Availability isn't the same as access.
The government announced this alongside funding for expensive cancer drugs and robotic surgery. Is that connected?
It's the full picture. Screening finds cancers earlier, when they're smaller and more treatable. But you still need the tools to treat them. Twenty-three new high-cost medications, robotic surgery capability—these are the next step. You screen, you diagnose, you treat. Without all three, screening alone becomes a cruel promise.
What happens if the system finds more cancers than it can handle?
That's the risk. Screening programs can overwhelm healthcare systems if capacity doesn't keep pace. Brazil's public system is already handling a 20 percent increase in chemotherapy and a 22 percent increase in radiation therapy. Adding millions of new screening results could create a bottleneck at colonoscopy and treatment. The announcement is ambitious. Whether the infrastructure can deliver is another question entirely.